Cargando…
State‐of‐the‐art treatment of systemic lupus erythematosus
As glucocorticoids and immunosuppressive drugs are non‐specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to control specific molecular targets is anticipated for the treatment of systemic lupus erythematosus (SLE). The antibody targeting B cell‐acti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187183/ https://www.ncbi.nlm.nih.gov/pubmed/32134201 http://dx.doi.org/10.1111/1756-185X.13817 |